H2020Индивидуална стипендия2019–2021

PTOoC · Plug-n-Play Tool-kit of Organ-on-Chips

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2019-10-11 → 2021-10-10
Финансиране от ЕС
196 708 €
Участници
1
Схема
MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Системите „орган на чип“ имитират средата на човешките клетки, за да се тества ефектът от нови лекарства. Това помага за по-точно предвиждане на реакцията на човешкия организъм и намалява разходите и зависимостта от опити върху животни.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Plug-n-Play Tool-kit of Organ-on-Chips

Pharmaceutical drugs are a critical aspect of the current health-care practices. The effectiveness of a given treatment protocol is highly dependent on efficacy of the drug being administered. The need for effective and high-quality health-care drives the pharmaceutical industry to discover and develop new drug molecules. Of late, there has been a staggering rise in the cost of bringing new drugs to the market. The use of animal based drug-testing protocols is one of the major reasons for this increasing developmental expenditure. In the initial phases, drugs are tested by administering them to animals (like mice, rabbits etc). Often drugs which clear the initial testing fail to demonstrate efficacy or prove to be harmful, when tested on humans at a later phase of testing. The lack of predictive insights early-on in the development cycle leads to failure of drug candidates in human clinical trials. At which point, the company would have typically invested years of time and billions of dollars in R&D costs. Due to the inherent differences in physiology (at a systemic-level) between animals and humans, animal based testing does not provide essential insights on whether a drug molecule would clear human clinical trials. The demand for testing systems with high physiological similarity to humans, while being cost-effective has led to the development of Organ-on-Chip (OoC) or Micro-Physiological Systems (MPS). Human physiology is incredibly complex at the systemic level and is different in many nuanced ways from the animals that are used to test drugs. Organ-on-chips (Oocs) efficiently mimic various aspects of the environment, in which cells are present within the human body. Evaluation of cellular response (to drugs) using OoCs would provide better predictive insights and reduce R&D expenses by identifying inviable drug molecules early-on. By leveraging advances from micro-scale fabrication, researchers have been able to demonstrate organ-level physiological response for the human heart, lung, liver, gut, kidney, skin, vasculature. OoCs have begun to make their way into the real-world, with the emergence of several start-ups trying to commercialize them. However, OoCs have yet to cross certain key barriers, for them to become the gold-standard method for drug testing. The current state-of-the-art in OoCs suffer from low standardization level, low through-put work-flows in comparison to their conventional cell culture-based counterparts. Further, the functional scaling of organ sizes and vascular flow warrants a major design constraint in the development of OoCs. The current project proposes to develop an modular approach to design and fabricate OoC systems. Such an approach will enable quick design and rapid prototyping of OoC systems, while instilling a high-level of standardization in the domain. Specifically, the main objective of the project was to design and develop a library of inter-lockable components, which can be used to construct any given organ-on-chip at the required physiological/functional scale. Each part of the library would serve to enable a certain physicochemical stimulus/structure warranting its use in the design of a specific type of organ-on-chip.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Off late, there has been a tremendous surge in the cost of bringing new drugs to the market. The rising costs and ethical concerns related to screening with animal models have led to the development of alternate approaches for drug discovery. Owing to the advantages of high physiological relevance and predictive value, Micro-physiological systems (MPSs) (also referred to as Organ-on-chips (OoC)) are gradually taking over as powerful and cost-effective alternative to animal model-based drug screening. However, OoCs have yet to cross certain key barriers, before they are adopted as an industry standard for drug screening. The current state-of-the-art in OoCs suffer from a low standardization level, low throughput workflow, in comparison to conventional cell culture-based methods. The main objective of the project is to design and develop a library of inter-lockable hard-soft hybrid components, which can be used to construct any given organ-on-chip at the required physiological/functional scale. Each part of the library would serve to enable a certain physicochemical stimulus/structure warranting its use in the design of a specific type of organ-on-chip. The overall library would contain all the required parts to enable implementation of different microenvironments from different organs of the human body. The development of such parts would enable a standardized approach to OoC development and testing across the industry. The project will have a preliminary focus on demonstrating the proof-of-concept for assembling a lung-on-chip OoC from the developed modular components. Followed by integration of different organ-on-chips with functional scaling and parallelization for high-throughput. The project has a strong multi-disciplinary nature with expertise involved from fields of engineering/mechanical design, microfluidics, biological cell culture/microbiology.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз